Alvotech and Dr. Reddy’s Collaborate on Biosimilar for Keytruda® (pembrolizumab)
Friday, June 06, 2025
Alvotech, a global biotechnology firm focused on developing and producing biosimilar medicines, has entered into a collaboration and licensing agreement with Dr. Reddy’s Laboratories to co-develop, manufacture, and commercialise a biosimilar version of Keytruda® (pembrolizumab) for global markets.
Keytruda is a widely used immunotherapy treatment for various cancers. In 2024, its global sales reached US$29.5 billion. Through this partnership, both companies aim to combine their strengths in biosimilars to support faster development and expand access to this treatment option worldwide.
As part of the agreement, both companies will share development and manufacturing duties as well as associated costs. Apart from certain exceptions, each partner will also have the right to market the biosimilar globally.
This collaboration is expected to strengthen their presence in oncology and improve the availability of affordable biologic therapies for patients around the world.
Source: globenewswire.com
